
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) **July 3, 2006**



(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction
of Incorporation)

0-30379
(Commission File Number)

88-0425691
(IRS Employer
Identification Number)

3661 Horseblock Road
Medford, NY 11763
(Address of principal executive offices)

631-924-1135
(Registrant's Telephone Number)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 3.02. Unregistered Sales of Equity Securities.

On July 3, 2006, the Company issued 322,577 shares of common stock as payment of dividends on the Company's series B preferred stock. No cash was exchanged in this issuance. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The investors in the issuance were accredited investors of the Company.

On July 10, 2006, the Company issued to Bio-Business Science & Development LTDA, in payment of commissions, warrants to purchase 29,838 shares of the Company's Common Stock having an exercise price of \$0.753 per share. These warrants are exercisable immediately and expire five years from the date of issue. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The sole investor in the issuance was an accredited investor.

On July 18, 2006, the Company issued 15,000 shares of Common Stock to one of the Company's non-employee directors, Alan Carus. The Common Stock vests in three equal annual installments beginning on July 1, 2006. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance.

On July 31, 2006, the Company issued to Investor Relations Group, Inc., in payment for consulting services, warrants to purchase 8,333 shares, of the Company’s Common Stock having an exercise price of \$0.70 per share and 8,333 shares of the Company’s Common Stock. The warrants are exercisable immediately and expire five years from the date of issue. The Company relied on Section 4(2) of the Securities Act of 1933 as the basis for its exemption from registration of this issuance. The sole investor in the issuance was an accredited investor.

ITEM 7.01. Regulation FD Disclosures.

- (a) On August 3, 2006 the Registrant issued the press release titled “Chembio Receives First Order from PEPFAR’s Supply Chain Management System” included herein as Exhibit 99.1.

ITEM 9.01. Financial Statements and Exhibits

- (c) Exhibits.

99.1 Press Release titled “[Chembio Receives First Order from PEPFAR’s Supply Chain Management System](#)” issued August 3, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: August 8, 2006

Chembio Diagnostics, Inc.

By: /s/ Lawrence A. Siebert
Lawrence A. Siebert
Chief Executive Officer



Chembio Receives First Order from PEPFAR's Supply Chain Management System

MEDFORD, N.Y. - August 3, 2006 - Chembio Diagnostics, Inc. (OTCBB:CEMI) has received its first order from the new Supply Chain Management System (SCMS) established recently under the auspices of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). The order is for 50,000 HIV 1/2 STAT-PAK(TM) tests to be used in connection with the ongoing scale-up of rapid testing in Nigeria. This ramp up in testing will be necessary in order for the country, one of the fifteen original PEPFAR focus countries, to meet its HIV treatment targets under PEPFAR and other programs.

SCMS is designed to improve the supply chain that delivers an uninterrupted supply of high-quality, affordable products abroad. The project will focus on better forecasting to determine what products are needed, as well as aggregating demand and improving systems for storage, transport and distribution. The SCMS supply chain will be transparent, accountable and tailored to specific country needs. The SCMS project team is led by the Partnership for Supply Chain Management (PSCM), a nonprofit organization established by JSI Research & Training Institute (JSI) and Management Sciences for Health (MSH). The project team includes 17 institutions including large multinationals Northrop Grumman Information Technology and UPS Supply Chain Solutions.

Chembio believes it is extremely well positioned to participate in ongoing procurements from SCMS as a result of its competitively priced, FDA-approved products that are manufactured in the United States. Further information on SCMS can be viewed at http://portalprd1.jsi.com/portal/page?_pageid=273,4810405,273_4810524&_dad=portal&_schema=PORTAL.

ABOUT CHEMBIO

Chembio Diagnostics, Inc., a developer and manufacturer of rapid diagnostic tests for infectious diseases, is on the frontlines of the global battle against the AIDS pandemic. The Company has received marketing approval from the FDA for its SURE CHECK(R) HIV 1/2 and HIV 1/2 STAT-PAK(TM) rapid tests. The Company also manufactures rapid tests for veterinary Tuberculosis and Chagas Disease, and has developed a patent-pending technology, the Dual Path Platform (DPP(TM)), for its next generation HIV and other rapid tests. For additional information please visit www.chembio.com.

FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements are estimates only, as the Company has not completed the preparation of its financial statements for those periods, nor has its auditor completed the audit of those results. Actual revenue may differ materially from those anticipated in this press release. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing, to obtain regulatory approvals in a timely manner, and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Contact:

The Investor Relations Group
Investors: James Carbonara/Andrea Raetzer
Media: Susan Morgenbesser
212-825-3210